Crizanlizumab is a monoclonal antibody drug that is used in the treatment and prevention of sickle cell disease. This drug works by blocking a protein in the body that triggers the formation of sickle cells, which can cause pain and other complications for patients. Although there are no direct synonyms for the drug name, it is often referred to as an anti-sickling agent or a sickle cell disease treatment. It is also sometimes called a biologic therapy or an immunotherapy since it is designed to target specific molecules in the body's immune system. While there are other drugs and therapies available to treat sickle cell disease, crizanlizumab is a promising new treatment option that may help patients better manage their symptoms and improve their quality of life.